AstraZeneca (AZN) Reports Q4 EPS of $1.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AstraZeneca (AZN) PT Raised to $42 at Bernstein; 'Catalyst-Rich Year'
February 5, 2018 7:44 AM ESTBernstein raised its price target on AstraZeneca (NYSE: AZN) to $42.00 (from $40.00) while maintaining a Outperform rating.
Analyst Tim Anderson said both Q4 and guidance were decent and 2018 remains a catalyst-rich year.
... More